Positive immunohistochemical labelling for MM versus BMP in cytological and histological studies
| Marker | Study type | BMP (%) | MM (%) | References; remarks |
|---|---|---|---|---|
| EMA | Cytology | 0–26 | 75–100 | 52 53 |
| EMA | Histology | <10–>50 | 77 for epithelioid MM | 49. King et al50 reviewed five histology studies, with sensitivity of 74% and 89% specificity for MM. See also Hammar et al9 |
| GLUT-1 | Cytology | 0–20 | ∼63–100 | 52 53 |
| GLUT-1 | Histology | 0–7 | 40–100 | 54–56 |
| IMP3 | Cytology | 0–6 | 36–73 | 53 57. In two cytology studies, GLUT-1 and IMP3 positivity was also found in 67–100% of secondary squamous cell carcinomas and adenocarcinomas53 58 |
| XIAP | Cytology | ∼10 | ∼80 | 59–61. XIAP positivity is recorded in ∼33–100% of carcinomas depending on the sites of origin59–61 |
| bd-2 | Histology | 0 | 3–11 | 49 62. See also King et al50 |
| p53 | Histology | 0 | 41–61 | 49 50 |
| Desmin | Cytology; histology | 84–85 | 8–10 | 49 63 |
Churg and Galateau-Sallé15 have also reviewed studies on such markers, and they outlined the 5-year survival rates for a series of 55 cases of MMs and ‘atypical mesothelial hyperplasia’ from the Mesopath Group in France, as evaluated by immunolabelling for desmin, EMA and p53, using a 10% rate of cell staining as a boundary point: for desmin, there was a 50% 5-year survival rate for each of <10% versus >10%. For EMA, 5-year survivals were ∼70% for <10% labelling and ∼35% with >10% labelling. For p53, the corresponding rates were ∼75% and 30%.
BMP, benign reactive mesothelial proliferation; EMA, epithelial membrane antigen; GLUT-1, glucose transporter-1; IMP3, insulin-like growth factor messenger RNA-binding protein 3; XIAT, X-linked inhibitor of apoptosis.